Webinar: What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer (2020)

August 25, 2020

Course Director: Judd W. Moul, MD

This course will include case-based presentations and ARS in three distinct diseases groups: hormone-sensitive metastatic prostate cancer (HSMPC); non-metastatic castrate resistant prostate cancer (M0CRPC) and metastatic CRPC (MCRPC) to educate urologists, APP's and their teams to identify and understand the many new FDA-approved agents, as well as existing standard therapies. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed. We aim to allow urologists and their practice teams to be comfortable prescribing various agents and understand systemic chemotherapy, PARP inhibitors and emerging immunotherapy.  Of particular interest are the new FDA-approvals for these patients in the last year for use in HSMPC and MOCRPC.

Acknowledgments

This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. List the three main advanced prostate cancer disease states (HSMPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice.
  2. Identify FDA-hormonal and non-hormonal therapies for use in each of these three disease states: HSMPC, M0 CRPC, M1 CRPC.
  3. Demonstrate the safe use and unique mechanism of action and side effects of new and existing agents.
  4. Explain the sequencing of novel therapies and be able to identify patient progression of disease by PSA, imaging and signs and symptoms.
  5. Work in team care including urologists, advanced practice providers, oncology nursing, oncology pharmacy, medical oncology and radiation oncology and their support staffs.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
06/29/2020
Course expires: 
08/25/2023
Event starts: 
08/25/2020 - 6:00pm EDT
Event ends: 
08/25/2020 - 7:30pm EDT
Part of: 
Summer School Webinar Series (2020)
Add to calendar: 
Rating: 
0

Scientific Agenda

6:00 pm               Welcome & Housekeeping

                            AUA

6:03 pm               Knowledge Assessment

                            Judd W. Moul, MD, FACS

6:08 pm              Course Director Introductions

                           Judd W. Moul, MD, FACS

6:10 pm              Metastatic Hormone Sensitive Prostate Cancer

                           Lawrence I. Karsh MD FACS

6:30 pm               Non Metastatic (MO) Castrate Resistant Prostate Cancer

                           Judd W Moul, MD, FACS

6:50 pm               Metastatic Castrate Resistant Prostate Cancer

                           Evan Y. Yu, MD

7:10 pm               Course Director/Faculty Q&A

                           All Faculty

7:25 pm               Course Director Wrap-up/Reminders

                            Judd W. Moul, MD, FACS

7:30  pm               Webinar Adjourns/Broadcast ends

What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer (2020) will be held virtually on Tuesday, August 25 at 6:00 PM EST.

***Instructions***

  1. Click the "Register" tab.
  2. If prompted, click “update your profile”. Otherwise, click “Take Course”.
  3. Click on the GoToWebinar link under Course Instructions to join the webinar.

Education Council Disclosures

PDF icon Education Council & COI Reviewer Disclosure_082620.pdf

AUA Office of Education Staff has nothing to disclose.

Course Director:

Judd Moul, MD, FACS

Course Faculty:

Lawrence I. Karsh, MD

Evan Y. Yu, MD

Course Director/Faculty Disclosures:  PDF icon Faculty Disclosures_Summer School_Whats New.pdf

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA Participant Information and Policies

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.

REPRODUCTION PERMISSION: 

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

To join the webinar:

  1. Click on the TAKE COURSE button.
  2. Click on the GoToWebinar link found under Course Instructions to join the webinar.